- Home
- NHIV vs LAB Comparison
NHIV vs LAB Comparison
Compare NHIV & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NHIV | LAB |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.5M | 326.2M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NHIV | LAB |
|---|---|---|
| Price | $10.12 | $0.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 5.3K | ★ 1.7M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | ★ N/A | $2.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.96 | $0.63 |
| 52 Week High | $10.16 | $1.72 |
Technical Indicators
Market Signals| Indicator | NHIV | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 38.50 |
| Support Level | $10.05 | N/A |
| Resistance Level | $10.16 | $0.99 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 63.64 | 22.82 |
Price Performance
Historical ComparisonAbout NHIV NewHold Investment Corp IV Class A Ordinary Shares
NewHold Investment Corp IV is a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.